You are here: Industry Insights > Alzheimer’s

News List

Leukine® is beneficial to patients with mild-to-moderate Alzheimer’s, finds study europeanpharmaceuticalreview
March 26, 2021
In a Phase II trial, Leukine® (sargramostim) significantly reduced biomarkers of neurodegeneration and improved cognitive function.
Salbutamol significantly increases cerebral perfusion in proof-of-concept trial europeanpharmaceuticalreview
March 17, 2021
In the Phase I trial, the beta-2 adrenoceptor agonist salbutamol significantly increased cerebral perfusion, a key biomarker in neurodegenerative disease.
Cassava Sciences Enters Drug Supply Agreement with Evonik contractpharma
March 10, 2021
Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam.
Oxford University to develop Alzheimer’s disease treatments with Exscientia pharmatimes
February 22, 2021
The Alzheimer’s Research UK Oxford Drug Discovery Institute (ARUK-ODDI) has announced a partnership with AI drug discovery company Exscientia on the development of therapies for Alzheimer’s disease.
XPro1595 significantly improves neurodegeneration in AD trial europeanpharmaceuticalreview
January 26, 2021
Treatment with XPro1595 for three months caused significant changes in neurodegeneration, synaptic function and neuroinflammation.
US approves Chinese drug maker Shanghai Green Valley’s Alzheimer’s therapy for large-scale clinical trials SCMP
April 27, 2020
A Chinese drug maker has received approval from the Food and Drug Administration to start clinical trials in the US for a breakthrough Alzheimer’s drug as it seeks global validation for the controversial therapy.
Eisai Continues Alzheimer's Research, Adds 2 Alzheimer's Pros as Execs biospace
May 05, 2019
The industry was shaken up when Tokyo-based Eisai and its collaboration partner, Biogen, announced they were abandoning huge swaths of their Alzheimer’s program related to aducanumab in late March.
AbbVie and Mission partner on Alzheimer’s and Parkinson’s drugs pharmaceutical-technology
November 20, 2018
AbbVie has collaborated with UK-based drug discovery firm Mission Therapeutics for research and preclinical development of potential therapies to treat Alzheimer’s disease and Parkinson’s disease.
Pain Therapeutics hit with yet another CRL, plots ‘reorganization,’ Alzheimer’s pivot fiercebiotech
August 07, 2018
With little surprise, Pain Therapeutics has been hit with a complete response letter from the FDA for Remoxy ER, its extended-release, capsule gel form of the opioid oxycodone.
Brain’s lymphatic system, just recently discovered, now linked to aging and Alzheimer’s fiercepharma
July 30, 2018
The accumulation of amyloid-beta in the brain is believed to be a culprit behind neurodegeneration, but the underlying mechanism of the buildup is not yet clear.

Previous page 1 2 3 Next page